secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017846
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q1 net loss $11.9M, cash $241.7M; programs advance
-------------------------------------------------------------------

- Net loss $11.9M vs $14.8M YoY; R&D expense $10.4M, G&A $3.9M.
- Cash and equivalents $241.7M, expected to fund operations >2 years.
- SURF301 Phase 1/2 of TYRA-300 for FGFR3+ tumors continues enrolling patients.
- TYRA-300 development expanded into achondroplasia; IND submission targeted in 2024.
- TYRA-200 IND cleared by FDA; Phase 1 for cholangiocarcinoma on track for 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017023017846/0000950170-23-017846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017023017846/tyra-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer